Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!   Read More

Earlier this week I reported that Dr. Allen Taylor who ran the Abbott vs. Merck cholesterol drug study, which Abbott's drug Niaspan won, would only say that ABT has paid him more than $10,000 in lecture and consulting fees. But he wouldn't be any more specific than that.    Read More

If you’re looking for stocks to buy and hold, here’s a strategy as well as a few names you should know about.   Read More

Stocks opened lower on Tuesday, after a sharp rally in the prior session. Where should investors be looking and how should they play the markets? David Spika, VP and investment strategist at WHG Funds and Bill Smead, CEO and CIO of Smead Capital Management shared their outlooks.    Read More

Live TV is best when things are happening and news is breaking right now. It's immediate and often, hopefully, more compelling.    Read More

It doesn't always happen, but there is a common to-and-fro, push-and-pull, back-and-forth or whatever you want to call it between reporters and corporate PR folks. I don't particularly like that part of my job, but sometimes it just comes with the territory. I've got my job to do and they've got theirs. I get it.    Read More

Both the charts and the fundamentals agree.   Read More

Many analysts, lobbyists and industry executives have been saying for months that healthcare reform would probably end up being a net positive for the drug companies.    Read More

On Saturday, the House backed a health care bill that would expand coverage to nearly all Americans and bar insurance practices such as refusing to cover people with pre-existing medical conditions. How should investors be positioned? Bob Phillips, managing partner at Spectrum Management Group and Robert Zagunis, co-portfolio manager at Jensen Investment Management shared their insights.    Read More

Markets rose on Wednesday despite a weaker-than-expected reading on the services sector. Is the economy in the middle of a recovery and if so, how can investors play it? Bill Spiropoulos, CEO of CoreStates Capital Advisors and John Merrill, founder and CIO of Tanglewood Wealth Management shared their insights.    Read More